Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1

Molecular Therapy

Volumn 21, Issue 6, 2013, Pages 1160-1168

  Heinrich, Tim ^a   Rengstl, Benjamin ^a   Muik, Alexander ^b   Petkova, Mina ^a   Schmid, Frederike ^a   Wistinghausen, Robin ^a   Warner, Kathrin ^c   Crispatzu, Giuliano ^c   Hansmann, Martin Leo ^a   Herling, Marco ^c   Von Laer, Dorothee ^d   Newrzela, Sebastian ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; JANUS KINASE 1; RETROVIRUS VECTOR; RUXOLITINIB; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE; JAK1 GENE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT OUTCOME; TUMOR CELL;

ANIMALIA;

EID: 84878523598     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.67     Document Type: Article

References (43)

1. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
2. Laufs, S, Nagy, KZ, Giordano, FA, Hotz-Wagenblatt, A, Zeller, WJ and Fruehauf, S (2004). Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol Ther 10: 874-881.
3. Bushman, F, Lewinski, M, Ciuff, A, Barr, S, Leipzig, J, Hannenhalli, S et al. (2005). Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol 3: 848-858.
4. Staal, FJ, Pike-Overzet, K, Ng, YY and van Dongen, JJ (2008). Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage? Leukemia 22: 1849-1852.
5. Li, Z, Düllmann, J, Schiedlmeier, B, Schmidt, M, von Kalle, C, Meyer, J et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
6. Hacein-Bey-Abina, S, Garrigue, A, Wang, G P, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
7. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
8. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
9. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204.
10. Avedillo Díez, I, Zychlinski, D, Coci, EG, Galla, M, Modlich, U, Dewey, RA et al. (2011). Development of novel effcient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm 8: 1525-1537.
11. Bonini, C, Grez, M, Traversari, C, Ciceri, F, Marktel, S, Ferrari, G et al. (2003). Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9: 367-369.
12. Scholler, J, Brady, TL, Binder-Scholl, G, Hwang, WT, Plesa, G, Hege, KM et al. (2012). Decade-long safety and function of retroviral-modifed chimeric antigen receptor T cells. Sci Transl Med 4: 132ra53.
13. Recchia, A, Bonini, C, Magnani, Z, Urbinati, F, Sartori, D, Muraro, S et al. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 103: 1457-1462.
14. Surh, CD and Sprent, J (2005). Regulation of mature T cell homeostasis. Semin Immunol 17: 183-191.
15. Hays, EF, Bristol, GC, McDougall, S, Klotz, JL and Kronenberg, M (1989). Development of lymphoma in the thymus of AKR mice treated with the lymphomagenic virus SL 3-3. Cancer Res 49: 4225-4230.
16. Newrzela, S, Cornils, K, Li, Z, Baum, C, Brugman, MH, Hartmann, M et al. (2008). Resistance of mature T cells to oncogene transformation. Blood 112: 2278-2286.
17. Newrzela, S, Cornils, K, Heinrich, T, Schläger, J, Yi, JH, Lysenko, O et al. (2011). Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes. Mol Med 17: 1223-1232.
18. Newrzela, S, Al-Ghaili, N, Heinrich, T, Petkova, M, Hartmann, S, Rengstl, B et al. (2012). T-cell receptor diversity prevents T-cell lymphoma development. Leukemia 26: 2499-2507.
19. Akagi, K, Suzuki, T, Stephens, RM, Jenkins, NA and Copeland, NG (2004) RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 32(Database issue): D523-D527.
20. Quintás-Cardama, A, Vaddi, K, Liu, P, Manshouri, T, Li, J, Scherle, PA et al. (2010). Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109-3117.
21. Meyer, J, Rhein, M, Schiedlmeier, B, Kustikova, O, Rudolph, C, Kamino, K et al. (2007). Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, deltaTrkA. Leukemia 21: 2171-2180.
22. Iqbal, J, Weisenburger, DD, Chowdhury, A, Tsai, MY, Srivastava, G, Greiner, TC et al.; International Peripheral T-cell Lymphoma Project. (2011). Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic d T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 25: 348-358.
23. Iqbal, J, Weisenburger, DD, Greiner, TC, Vose, JM, McKeithan, T, Kucuk, C et al.; International Peripheral T-Cell Lymphoma Project. (2010). Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115: 1026-1036.
24. Piccaluga, P P, Agostinelli, C, Califano, A, Rossi, M, Basso, K, Zupo, S et al. (2007). Gene expression analysis of peripheral T cell lymphoma, unspecifed, reveals distinct profles and new potential therapeutic targets. J Clin Invest 117: 823-834.
25. Travert, M, Huang, Y, de Leval, L, Martin-Garcia, N, Delfau-Larue, MH, Berger, F et al. (2012). Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 119: 5795-5806.
26. van Doorn, R, van Kester, MS, Dijkman, R, Vermeer, MH, Mulder, AA, Szuhai, K et al. (2009). Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 113: 127-136.
27. de Leval, L, Rickman, DS, Thielen, C, Reynies, Ad, Huang, YL, Delsol, G et al. (2007). The gene expression profle of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109: 4952-4963.
28. Dürig, J, Bug, S, Klein-Hitpass, L, Boes, T, Jöns, T, Martin-Subero, JI et al. (2007). Combined single nucleotide polymorphism-based genomic mapping and global gene expression profling identifes novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32). Leukemia 21: 2153-2163.
29. Shin, J, Monti, S, Aires, DJ, Duvic, M, Golub, T, Jones, DA et al. (2007). Lesional gene expression profling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 110: 3015-3027.
30. Eckerle, S, Brune, V, Döring, C, Tiacci, E, Bohle, V, Sundström, C et al. (2009). Gene expression profling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 23: 2129-2138.
31. Lamant, L, de Reyniès, A, Duplantier, MM, Rickman, DS, Sabourdy, F, Giuriato, S et al. (2007). Gene-expression profling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109: 2156-2164.
32. Deeks, SG, Wagner, B, Anton, PA, Mitsuyasu, RT, Scadden, DT, Huang, C et al. (2002). A phase II randomized study of HIV-specifc T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5: 788-797.
33. Mitsuyasu, RT, Anton, PA, Deeks, SG, Scadden, DT, Connick, E, Downs, MT et al. (2000). Prolonged survival and tissue traffcking following adoptive transfer of CD4zeta gene-modifed autologous CD4(+) and CD8(+) T cells in human immunodefciency virus-infected subjects. Blood 96: 785-793.
34. Walker, RE, Bechtel, CM, Natarajan, V, Baseler, M, Hege, KM, Metcalf, JA et al. (2000). Long-term in vivo survival of receptor-modifed syngeneic T cells in patients with human immunodefciency virus infection. Blood 96: 467-474.
35. Migone, TS, Lin, JX, Cereseto, A, Mulloy, JC, O'Shea, JJ, Franchini, G et al. (1995). Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269: 79-81.
36. Yu, CL, Jove, R and Burakoff, SJ (1997). Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol 159: 5206-5210.
37. Flex, E, Petrangeli, V, Stella, L, Chiaretti, S, Hornakova, T, Knoops, L et al. (2008). Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 205: 751-758.
38. Zhang, Q, Raghunath, PN, Xue, L, Majewski, M, Carpentieri, DF, Odum, N et al. (2002). Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168: 466-474.
39. Khoury, JD, Medeiros, LJ, Rassidakis, GZ, Yared, MA, Tsioli, P, Leventaki, V et al. (2003). Differential expression and clinical signifcance of tyrosine-phosphorylated STAT3 in ALK+ and ALK-anaplastic large cell lymphoma. Clin Cancer Res 9(10 Pt 1): 3692-3699.
40. Sommer, VH, Clemmensen, OJ, Nielsen, O, Wasik, M, Lovato, P, Brender, C et al. (2004). In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18: 1288-1295.
41. Schambach, A, Wodrich, H, Hildinger, M, Bohne, J, Kräusslich, HG and Baum, C (2000). Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2: 435-445.
42. Newrzela, S, Gunda, B and von Laer, D (2009). T cell culture for gammaretroviral transfer. Methods Mol Biol 506: 71-82.
43. Li, LC and Dahiya, R (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.